



**ANNUAL GENERAL MEETING
OF ARGEN-X N.V. OF 28 APRIL 2016**

AGENDA

1. Opening
2. Report on the 2015 financial year (*discussion item*)
3. Discussion and adoption of the 2015 annual report and annual accounts:
 - a. Discussion of the 2015 annual report (*discussion item*)
 - b. Adoption of the 2015 annual accounts (*voting item*)
 - c. Corporate governance statement (*discussion item*)
 - d. Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2015 (*voting item*)
 - e. Allocation of losses of the Company in the financial year 2015 to the retained earnings of the Company (*voting item*)
4. Amendment of the articles of association of arGEN-X N.V. (and granting a proxy to each of the directors of the Company and employees of Osborne Clarke N.V. in having the deed of amendment executed) (*voting item*)
5. Appointment of P. Klein as non-executive director to the board of directors of the Company (*voting item*)
6. Explanation of the implementation of the remuneration policy in 2015 (*discussion item*)
7. Approval of new remuneration policy (*voting item*)
8. Approval of the amended argenx option plan (*voting item*)
 - a. Authorization of the board of directors to grant options pursuant to, and within the limits of, the (amended) argenx option plan, for a period of 18 months from the general meeting (*voting item*)
 - b. Authorization of the board of directors to issue shares pursuant to the exercise of vested options under the argenx option plan, for a period of 18 months from the general meeting (*voting item*)
9. Authorization of the board of directors to issue shares in the share capital of the Company up to a maximum of 20% of the outstanding capital at the date of the general meeting, for a period of 18 months from the general meeting, *in addition* to the authorization to issue shares pursuant to the exercise of options (*voting item*)
10. Authorization of the board of directors to, insofar necessary, limit or exclude pre-emptive rights with regard to an issuance of new shares for a period of 18 months from the general meeting (*voting item*)
11. Appointment of Deloitte Accountants B.V. for the 2016 financial year (*voting item*)
12. Any other business, announcements or questions
13. End of the annual general meeting

All shareholders are requested to attend the meeting.

Breda, 16 March 2016

Board of directors arGEN-X N.V.